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Abstract
Purpose: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR
mutant lung cancer, patients ultimately develop resistance by multiple mechanisms. We therefore assessed the
ability of combined treatment with the Met inhibitor crizotinib and new generation EGFR-TKIs to overcome resistance
to first-generation EGFR-TKIs.
Experimental Design: Lung cancer cell lines made resistant to EGFR-TKIs by the gatekeeper EGFR-T790M
mutation, Met amplification, and HGF overexpression and mice with tumors induced by these cells were treated with
crizotinib and a new generation EGFR-TKI.
Results: The new generation EGFR-TKI inhibited the growth of lung cancer cells containing the gatekeeper EGFR-
T790M mutation, but did not inhibit the growth of cells with Met amplification or HGF overexpression. In contrast,
combined therapy with crizotinib plus afatinib or WZ4002 was effective against all three types of cells, inhibiting
EGFR and Met phosphorylation and their downstream molecules. Crizotinib combined with afatinib or WZ4002
potently inhibited the growth of mouse tumors induced by these lung cancer cell lines. However, the combination of
high dose crizotinib and afatinib, but not WZ4002, triggered severe adverse events.
Conclusions: Our results suggest that the dual blockade of mutant EGFR and Met by crizotinib and a new
generation EGFR-TKI may be promising for overcoming resistance to reversible EGFR-TKIs but careful assessment
is warranted clinically.
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Introduction
Lung cancers with mutations that activate epidermal growth
factor receptor (EGFR), including exon 19 deletions and the
exon 21 L858R point mutation, respond to the reversible
EGFR-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and
erlotinib [1]. These mutations have been shown to promote the
activation of EGFR signaling and tumor dependency on EGFR.
Recent clinical trials have shown that progression-free survival
(PFS) in patients with EGFR mutant lung cancer is prolonged
by treatment with a reversible EGFR-TKI and the irreversible
EGFR-TKI afatinib, which was designed to covalently bind to
EGFR [2-5]. Nevertheless, almost all responders relapse after
acquiring resistance to these EGFR-TKIs [1,6]. Among the
mechanisms by which cancer cells become resistant to
reversible EGFR-TKIs are 1) gatekeeper mutations in EGFR,
such as the T790M second mutation [7,8]; 2) activation of
bypass signaling caused by Met amplification [9], hepatocyte
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growth factor (HGF) overexpression [10], or Gas6-Axl
activation [11]; 3) activation of downstream molecules (PTEN
loss or PIK3CA mutation) [12,13]; 4) small-cell lung cancer
transformation [14]; and 5) epithelial-to-mesenchymal transition
[15]. The gatekeeper EGFR-T790M mutation is the most
frequent, occurring in half of tumors with acquired resistance to
reversible EGFR-TKIs. The methionine residue at position 790
generates a bulkier side chain, which enhances the affinity of
the EGFR tyrosine kinase pocket with ATP [7], decreasing the
effective binding of gefitinib and erlotinib to the tyrosine kinase
pocket of EGFR [16]. To overcome acquired resistance, a new
generation of EGFR-TKIs was developed, including irreversible
EGFR-TKIs and mutant-selective EGFR-TKIs [17-22]. In
clinical trials, however, several of these irreversible EGFR-TKIs
failed to meet their primary endpoints in EGFR-TKI-refractory
lung cancer and induced severe toxicities, such as diarrhea,
skin rash/acne, stomatitis, and nail effects [1,20].
HGF, the sole ligand of Met, is important in the development
of EGFR-TKI resistance in EGFR mutant lung cancer cells.
HGF activates Met phosphorylation and stimulates the
downstream Akt and Erk1/2 pathways utilizing Gab1, an
adaptor protein for Met, triggering resistance to both reversible
and irreversible EGFR-TKIs [10,23,24]. In our previous
Japanese cohort study of patients with EGFR mutant lung
cancer, high HGF expression was detected in 61% of tumors
with acquired resistance and in 29% of tumors with intrinsic
resistance to EGFR-TKIs, suggesting that targeting HGF may
overcome resistance to EGFR-TKIs [25].
Resistance to molecular targeting agents may be caused by
tumor heterogeneity. For example, we and other researchers
reported that HGF overexpression can exist together with
gatekeeper EGFR-T790M mutation or Met gene amplification
in EGFR mutant lung cancer with acquired resistance to
EGFR-TKIs [23,25]. Therefore, HGF-Met axis signaling can
allow tumors to bypass the effects of new generation EGFR-
TKIs. Agents that overcome resistance to EGFR inhibitors,
especially by HGF-Met bypass signaling, are urgently needed.
Crizotinib is a dual tyrosine kinase inhibitor of ALK and Met that
shows potent anti-tumor activity, safety and feasibility as
monotherapy in lung cancer patients with EML4-ALK
rearrangements [26]. We have therefore evaluated the efficacy
and feasibility of combinations of crizotinib and new generation
EGFR inhibitors in overcoming the resistance to EGFR-TKIs of
lung cancer cells harboring EGFR mutations.
Materials and Methods
Cell cultures and reagents
The EGFR mutant human lung adenocarcinoma cell lines
PC-9 (del E746_A750) and HCC827, with deletions in EGFR
exon 19, were purchased from Immuno-Biological Laboratories
Co. (Takasaki, Gunma, Japan) and the American Type Culture
Collection (Manassas, VA), respectively. HCC827ER cells, with
deletions in EGFR exon 19 and Met gene amplification [27],
and H1975 cells, with the L858R/T790M double mutation in
EGFR [28], were kindly provided by Drs. Kenichi Suda and
Tetsuya Mitsudomi (Aichi Cancer Center Hospital, Nagoya,
Japan), and by Drs. Yoshitaka Sekido (Aichi Cancer Center
Research Institute, Japan) and John D. Minna (University of
Texas Southwestern Medical Center), respectively. PC-9/
KGR1, with deletions in EGFR exon 19 and the T790M double
mutation (Table 1), were established from PC-9 cells after the
stepwise exposure to gefitinib in 2011 at Kanazawa University
(Kanazawa, Japan). These cell lines were maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum
(FBS), penicillin (100 U/mL), and streptomycin (50 g/mL), in a
humidified CO2 incubator at 37°C. The MRC-5 lung embryonic
fibroblast cell line was obtained from RIKEN Cell Bank. MRC-5
(P 25–30) cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% FBS, penicillin (100
U/mL), and streptomycin (50 g/mL), in a humidified CO2
incubator at 37°C.
The characteristics of these cell lines are summarized in
Table 1. All cells were passaged for less than 3 months before
renewal from frozen, early-passage stocks. Cells were
regularly screened for mycoplasma, using MycoAlert
Mycoplasma Detection Kits (Lonza, Rockland, ME). Crizotinib,
afatinib, and WZ4002 were obtained from Selleck Chemicals
(Houston, TX). Erlotinib was obtained from Chugai
Pharmaceutical Co. Ltd. (Tokyo, Japan). Human recombinant
HGF was prepared as described [29].
HGF gene transfection
One day before transfection, aliquots of 1×105 HCC827 and
H1975 cells in 1 ml of antibiotic-free medium were plated on 6-
well plates. Full-length HGF cDNA cloned into the BCMGSneo
Table 1. Status of EGFR mutation and Met amplification










HCC827 E746_A750del - <0.03
HCC827ER E746_A750del + <0.03
HCC827/Vec E746_A750del - <0.03
HCC827/
HGF#24 E746_A750del - 284±29
HCC827/
HGF#28 E746_A750del - 121±21
PC-9 E746_A750del - <0.03
PC-9 KGR1 E746_A750del/T790M - <0.03
H1975 L858R/T790M - <0.03
H1975/Vec L858R/T790M - <0.03
H1975/HGF L858R/T790M - 370±24
MRC-5 wild - 88±9.0
doi: 10.1371/journal.pone.0084700.t001
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expression vector [30] was transfected using Lipofectamine
2000 in accordance with the manufacturer’s instructions. After
24 h, the cells were washed with PBS and incubated for an
additional 72 h in antibiotic-containing medium, followed by
selection in G418 sulfate (Calbiochem, La Jolla, CA). After
limiting dilution, HGF-producing cells, HCC827/HGF#24,
HCC827/HGF#28, and H1975/HGF, and vector control
(HCC827/Vec and H1975/Vec) were established. HGF
production by HCC827/HGF#24, HCC827/HGF#28, and
H1975/HGF cells was confirmed by ELISA.
Cell growth assay
Cell proliferation was measured by the MTT dye reduction
method [31]. Tumor cells, plated at 2 × 103/100 μL RPMI 1640
plus 10% FBS per well in 96-well plates, were incubated for 24
hours; afatinib, WZ4002, and crizotinib, and/or HGF were
added to each well, and incubation was continued for a further
72 hours. Cell growth was measured with MTT solution (2
mg/mL; Sigma, St. Louis, MO), as described [10]. Each
experiment was performed at least 3 times, each with triplicate
samples.
Antibodies and western blotting
Protein aliquots of 25 μg each were resolved by SDS
polyacrylamide gel (Bio-Rad, Hercules, CA) electrophoresis
and transferred to polyvinylidene difluoride membranes (Bio-
Rad). After washing 3 times, the membranes were incubated
with Blocking One (Nacalai Tesque, Inc., Kyoto, Japan) for 1
hour at room temperature and then incubated overnight at 4°C
with primary antibodies to Met (25H2), phospho-Met (anti-p-
Met, Y1234/Y1235; 3D7), p-EGFR (Y1068), Akt, p-Akt (S473)
(Cell Signaling Technology, Beverly, MA); human EGFR (1 μg/
mL), human/mouse/rat ERK1/ERK2 (0.2 μg/mL), and p-ERK1/
ERK2 (T202/Y204; 0.1 μg/mL) (R&D Systems, Minneapolis,
MN). After washing thrice, the membranes were incubated for 1
hour at room temperature with species-specific horseradish
peroxidase–conjugated secondary antibodies. Immunoreactive
bands were visualized with SuperSignal West Dura Extended
Duration Substrate, an enhanced chemiluminescent substrate
(Pierce Biotechnology, Rockford, IL). Each experiment was
performed at least thrice independently.
Co-culture of lung cancer cells with fibroblasts
Cells were co-cultured in Transwell Collagen-Coated
chambers separated by an 8-μm pore sized filter (BD
Biosciences, Erembodegem, Belgium). MRC-5 (1 × 104
cells/300 μL) cells were placed in the upper chamber and
incubated in the presence or absence of anti-human HGF
antibody (5 μg/mL) or crizotinib (100 nmol/L) for 2 hours.
Tumor cells (8 × 103 cells/800 μL), with or without afatinib (100
nmol/L) or WZ4002 (100 nmol/L) were placed in the lower
chamber and co-cultured with the MRC-5 cells (1 × 104
cells/300 μL) in the upper chamber for 72 hours. The upper
chamber was then removed, 200 µL of MTT solution (2 mg/mL;
Sigma) were added to each well and the cells were incubated
for 2 hours at 37°C. The media were removed and the dark
blue crystals in each well were dissolved in 400 μL of DMSO.
Absorbance was measured with an MTP-120 microplate reader
(Corona Electric) at test and reference wavelengths of 550 nm
and 630 nm, respectively. The percentage growth was
measured relative to untreated controls. All samples were
assayed at least in triplicate, with each experiment performed
three times independently.
Subcutaneous xenograft models
Suspensions of H1975/Vec and H1975/HGF cells (5×106)
were injected subcutaneously into the backs of 5-week-old
female severe combined immunodeficiency (SCID) mice (Clea,
Tokyo, Japan). After 6 days, the mice were randomized to (a)
no treatment (control group), (b) oral afatinib (25 mg/kg/daily),
(c) oral WZ4002 (25 mg/kg/daily), (d) low dose oral crizotinib
(10 mg/kg/daily), (e) high dose oral crizotinib (25 mg/kg/daily),
(f) afatinib plus low dose crizotinib, (g) afatinib plus high dose
crizotinib, (h) WZ4002 plus low dose crizotinib, and (i) WZ4002
plus high dose crizotinib. Tumor size and mouse body weight
were measured twice per week, and tumor volume was
calculated, in mm3, as width2 × length/2. This study was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the Ministry of
Education, Culture, Sports, Science and Technology in Japan.
The protocol was approved by the Committee on the Ethics of
Experimental Animals, Advanced Science Research Center,
Kanazawa University, Kanazawa, Japan (approval no.
AP-132618). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to minimize
suffering.
Histological analyses of tumors
Apoptotic cells were detected by terminal deoxynucleotidyl
transferase–mediated nick end labeling, using the DeadEndTM
Fluorometric TUNEL system (Promega, Madison, WI). Briefly,
formalin fixed, paraffin embedded tissue sections (4 μm thick)
were deparaffinized and tissues were permeabilized with
protease K solution. The samples were equilibrated, and DNA
strand breaks were labeled with fluorescein-12-dUTP
(fluorescein-12-2-deoxy-uridine-5-triphosphate) by adding
nucleotide mixture and TUNEL. The reaction was stopped by
the addition of saline sodium citrate, and the localized green
fluorescence of apoptotic cells was detected by fluorescence
microscopy (×400).
Proliferating cells were detected by incubating tissue
sections with Ki-67 antibody (Clone MIB-1; DAKO Corp,
Glostrup, Denmark). Antigen was retrieved by microwaving
tissue sections in 10 mM citrate buffer (pH 6.0). After
incubation with secondary antibody and treatment with the
Vectastain ABC Kit (Vector Laboratories, Burlingame, CA),
peroxidase activity was visualized using the DAB reaction. The
sections were counterstained with hematoxylin.
Quantification of immunohistochemistry and
immunofluorescence results
The five areas containing the highest numbers of stained
cells within each section were selected for histologic
quantitation by light or fluorescent microscopy at 400-fold
magnification. All results were independently evaluated by two
investigators (S.N. and T.Y.).
Crizotinib Overcomes Resistance to EGFR Inhibitors
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e84700
Histological analysis and quantification of intestinal
mucosal damage
Sections were stained with hematoxylin and eosin for routine
histologic examinations. Mucosal damage was scored as;
normal (0), mild mucosal atrophy (1), moderate mucosal
atrophy (2), and severe mucosal atrophy and/or ulcer formation
(3) in both the small and large intestines. The two areas within
a section in each group of 5 mice were histologically
quantitated by microscopy at 400-fold magnification, with
scores ranging 0 to 12. All results were independently
evaluated by two investigators (H.N. and S.N.).
RNA interference
Duplexed Stealth RNAi (Invitrogen) against Met and ALK,
and Stealth RNAi Negative Control Low GC Duplex #3
(Invitrogen) were used for RNA interference (RNAi) assays.
Briefly, aliquots of 1 × 105 cells in 2 mL of antibiotic-free
medium were plated into each well of a 6-well plate and
incubated at 37°C for 24 hours. The cells were transfected with
siRNA (250 pmol) or scrambled RNA using Lipofectamine 2000
(5 μL) in accordance with the manufacturer’s instructions
(Invitrogen). After 24 hours, the cells were washed twice with
PBS and incubated in the presence or absence of afatinib (100
nmol/L) or HGF (50 ng/mL) for an additional 48 hours in
antibiotic-containing medium. These tumor cells were then
used for cell proliferation assays, with Met and ALK
knockdowns confirmed by western blotting. The siRNA target
sequences were 5'-UCCAGAAGAUCAGUUUCCUAAUUCA-3'
and 5'-UGAAUUAGGAAACUGAUCUUCUGGA-3' for Met and
5'-UCAUUAUCCGGUAUACAGGCCCAGG-3' and 5'-
CCUGGGCCUGUAUACCGGAUAAUGA-3' for ALK. Each
assay was performed using triplicate samples, with three
independent experiments performed.
HGF production in cell culture supernatants
Cells (1 x 105) were cultured in 2 mL of RPMI 1640 or DMEM
with 10% FBS for 24 hours, washed with PBS and incubated
for 48 hours in RPMI 1640 with 10% FBS. The culture media
were harvested and centrifuged, and the supernatants were
stored at –70°C until analysis. HGF was measured by ELISA
(Immunis HGF EIA; B-Bridge International, Mountain View, CA;
limit of detection, 0.1 ng/mL), according to the manufacturer’s
instructions. All samples were assayed in triplicate. Color
intensity at 450 nm was measured with a spectrophotometric
plate reader. Growth factor concentrations were determined by
comparison with standard curves.
Statistical analysis
The statistical significance of differences was analyzed by
one-way ANOVA performed with GraphPad Prism Ver. 4.01
(GraphPad Software, Inc., San Diego, CA, USA). In all
analyses, P < 0.05 was defined as statistically significant.
Results
Crizotinib and a new generation EGFR-TKI overcomes
resistance to new generation EGFR-TKI in lung cancer
cells harboring EGFR mutations
We tested crizotinib plus a new generation EGFR-TKI,
irreversible EGFR-TKI afatinib (Figure 1) or mutant-selective
EGFR-TKI WZ4002 (Figure 2), with HGF induced resistance
for several cell lines by the MTT assay. In the first set of
experiments, we utilized PC-9 and HCC827 cells, which are
human lung adenocarcinoma cell lines with deletions of exon
19 of EGFR, resulting in activation of this gene. HCC827 cells
were treated with increasing doses of a new generation EGFR-
TKI in the presence of HGF alone, crizotinib alone, or HGF
pulse crizotinib, and cell proliferation was assessed. While a
new generation EGFR-TKI alone reduced cell proliferation,
exogenously added HGF caused resistance to a new
generation EGFR-TKI treatment in both cell lines. HGF-induced
resistance to a new generation EGFR-TKI was abrogated by
co-treatment with crizotinib (Figures 1A, 2A). Similar results
were obtained for PC-9 cells (Figures 1F, 2F). We next tested
H1975, a human lung adenocarcinoma cell line with both an
exon 20 T790M gatekeeper mutation and an exon 21 L858R
mutation in EGFR; and PC-9/KGR1, a cell line with both an
exon 20 T790M gatekeeper mutation and deletions of EGFR
exon 19. Although both cell lines were resistant to erlotinib
(data not shown), they were sensitive to a new generation
EGFR-TKI, and HGF induced hyposensitivity in a dose
dependent manner (Figure S1, S2). Crizotinib sensitized
H1975 cells to a new generation EGFR-TKI even in the
presence of HGF (Figures 1H, 2H). Similar results were
obtained for PC-9/KGR1 cells (Figures 1G, 2G). We also
examined the effect of these compounds in the HCC827ER cell
line, with a deletion of EGFR exon 19 and Met gene
amplification. HCC827ER cells were resistant to a new
generation EGFR-TKI, and HGF induced mild hyposensitivity.
However, crizotinib plus a new generation EGFR-TKI markedly
inhibited the growth of HCC827ER cells (Figures 1B, 2B).
Taken together, these results suggest that crizotinib plus either
afatinib or WZ4002 may overcome the resistance to reversible
EGFR-TKIs of EGFR mutant lung cancer cells containing an
EGFR gatekeeper mutation, Met gene amplification, and/or
HGF overexpression.
We previously reported that, in NSCLC patients, HGF is
present mainly in cancer cells with acquired resistance to
EGFR-TKIs, suggesting that HGF may be produced
predominantly in resistant tumor cells via an autocrine
mechanism [25]. To further explore the effect of dual inhibition
of EGFR and Met on autocrine production of HGF, we
generated stable HGF-gene transfectants in HCC827
(HCC827/HGF#24, and HCC827/HGF#28) and H1975 (H1975/
HGF) cells; as a control, we generated HCC827/Vec cells and
H1975/Vec cells, which were transfected with vector alone
(Table 1). HCC827/HGF#24, HCC827/HGF#28, and
H1975/HGF cells secreted high levels of HGF (284±29,
121±21, and 370±24 ng/ 105 cells/ 24 h, respectively), whereas
the concentrations of HGF secreted by HCC827/Vec and
H1975/Vec cells were under the limit of detection. HCC827/Vec
Crizotinib Overcomes Resistance to EGFR Inhibitors
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(Figures 1C, 2C) and H1975/Vec (Figures 1I, 2I) cells were
sensitive to a new generation EGFR-TKI, whereas HCC827/
HGF#24 (Figures 1D, 2D), HCC827/HGF#28 (Figures 1E, 2E),
and H1975/HGF (Figures 1J, 2J) cells became resistant to
these agents. The combination of crizotinib plus afatinib or
WZ4002 inhibited the growth of HCC827/HGF#24, HCC827/
HGF#28, and H1975/HGF cells. To further confirm that
crizotinib acted on Met in cells with HGF-induced resistance to
the new generation EGFR-TKIs, we knocked down Met or ALK
by specific siRNAs in H1975 cells (Figure S3). H1975 cell line
expressed no detectable level of wild type ALK or rearranged
ALK protein. Treatment with Met, but not ALK, siRNA reversed
the HGF-induced resistance to afatinib and WZ4002, indicating
that crizotinib acts via the Met pathway in HGF-induced
resistance to the new generation EGFR-TKIs. Taken together,
these findings indicated that the Met inhibitor crizotinib plus a
new generation EGFR-TKI, either afatinib or WZ4002,
circumvented resistance to HGF in an autocrine manner, in the
presence or absence of the EGFR T790M mutation or Met
gene amplification.
Crizotinib overcomes resistance to new generation
EGFR-TKIs induced by fibroblast-derived HGF
Because host microenvironments can have a profound effect
on the chemosensitivity of cancers and because stromal
fibroblasts are the major sources of HGF [32], we assayed
HGF production by human fibroblast cell lines. We found that
the human embryonic lung-derived fibroblast cell line MRC-5
secreted high levels of HGF into the supernatant. In contrast,
HCC827 and H1975 cells did not secrete detectable levels of
HGF into the culture supernatant (Table 1). To further
investigate whether the resistance of HCC827 and H1975 cells
to afatinib or WZ4002 was affected by crosstalk with stromal
fibroblasts, we cocultured lung cancer and MRC-5 cells in
Transwell systems. We found that coculture of HCC827 and
H1975 cells with MRC-5 cells did not significantly affect the
Figure 1.  Crizotinib overcomes HGF triggered resistance to irreversible EGFR-TKIs in EGFR-TKI resistant lung cancer
cells harboring EGFR mutations.  Tumor cells (2×103 cells per well) were incubated with various concentrations of afatinib, with or
without crizotinib (300 nmol/L) and/or HGF (10 ng/mL), for 72 hours. Cell growth was determined by the MTT assay. The
percentage of growth is shown relative to untreated controls. Each sample was assayed in triplicate, with each experiment repeated
at least 3 times independently.
doi: 10.1371/journal.pone.0084700.g001
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proliferation of the former. In the presence of MRC-5 cells,
however, HCC827 and H1975 cells became resistant to
afatinib and WZ4002, a resistance abrogated by treatment with
crizotinib (100 nmol/L) (Figure S4). These results indicate that
crizotinib can overcome the resistance to new generation
EGFR-TKIs induced by fibroblast-derived HGF in a paracrine
manner.
Crizotinib reduces Met phosphorylation and combined
treatment with a new generation EGFR-TKI inhibits
downstream pathways even in the presence of HGF
To explore the molecular mechanism by which combined
treatment with crizotinib and afatinib (Figure 3A, 3B) or
WZ4002 (Figure 3B, 3D) inhibited cell growth in the presence
of HGF, we examined the phosphorylation status of Met,
EGFR, and their downstream molecules (PI3K/Akt and
ERK1/2) in H1975 and H1975/HGF cells by western blotting.
These two cells expressed EGFR and Met proteins, both of
which were phosphorylated, and the downstream molecules
Akt and ERK1/2. While HGF alone did not affect the
phosphorylation of EGFR, it stimulated the phosphorylation of
Met, thereby activating Akt and ERK1/2. In the absence of
HGF, EGFR-TKI inhibited the phosphorylation of EGFR, but
not of Met, thereby inhibiting the phosphorylation of Akt and
ERK1/2. In the presence of HGF, EGFR-TKI failed to inhibit the
phosphorylation of Met, Akt and ERK1/2, although it inhibited
EGFR phosphorylation. Thus, the combination of crizotinib and
a new generation EGFR-TKI inhibited the phosphorylation of
EGFR and Met, and of their receptors and downstream
molecules, Akt and ERK1/2, irrespective of the presence of
HGF. Similar results were observed in H1975/HGF cells. These
results suggested that crizotinib plus the new generation
EGFR-TKI overcome resistance to HGF, predominantly by
inhibiting the phosphorylation of EGFR and Met proteins,
followed by inhibition of downstream Akt and ERK1/2.
Figure 2.  Crizotinib overcomes HGF triggered resistance to mutant-selective EGFR-TKIs in EGFR-TKI resistant lung
cancer cells harboring EGFR mutation.  Tumor cells (2×103 cells per well) were incubated with various concentrations of
WZ4002, with or without crizotinib (300 nmol/L) and/or HGF (10 ng/mL), for 72 hours. Cell growth was determined by the MTT
assay. The percentage of growth is shown relative to untreated controls. Each sample was assayed in triplicate, with each
experiment repeated at least 3 times independently.
doi: 10.1371/journal.pone.0084700.g002
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Combined treatment with crizotinib and a new
generation EGFR-TKI overcomes multiple resistance
mechanisms to EGFR-TKI in vivo
We next evaluated whether crizotinib plus afatinib (Figure
4A) or WZ4002 (Figure 5A) could overcome resistance to
EGFR-TKI caused by the gatekeeper EGFR-T790M mutation
and/or HGF overexpression in vivo. Oral administration to mice
of afatinib or WZ4002, with or without crizotinib, but not
crizotinib alone, markedly inhibited the growth of H1975/Vec-
tumors with the gatekeeper EGFR-T790M mutation. None of
these three agents alone inhibited the growth of H1975/HGF-
tumors, which both overexpress HGF and have the gatekeeper
EGFR-T790M mutation, indicating that HGF induced resistance
to the new generation EGFR-TKIs in vivo. In contrast, the
combination of afatinib or WZ4002 plus 10mg/kg crizotinib
markedly suppressed the growth of H1975/HGF tumors. A
greater degree of growth suppression was observed with
WZ4002 plus 25mg/kg crizotinib than WZ4002 plus 10mg/kg
crizotinib (Figure 5A). These results indicated that the addition
of crizotinib may overcome in vivo resistance to the new
generation of EGFR-TKIs induced by HGF overexpression and
the EGFR-T790M mutation.
Combined treatment with crizotinib and a new
generation EGFR-TKI decreases cell proliferation and
increases cell apoptosis in vivo by inhibiting of EGFR
and Met phosphorylation
To assess the mechanism of action of combined therapy, we
assayed the phosphorylation status of target molecules in
H1975/Vec- and H1975/HGF-induced tumors by western
blotting (Figure 4B, 5B). EGFR-TKIs inhibited the
phosphorylation of EGFR, Akt, and ERK1/2 in H1975/Vec-, but
not in H1975/HGF-induced tumors. The combination of afatinib
(Figure 4B) or WZ4002 (Figure 5B) plus crizotinib inhibited the
phosphorylation of EGFR and Met proteins, as well as the
phosphorylation of their receptors and downstream molecules,
Akt and ERK1/2, in mouse tumors induced by H1975/Vec and
H1975/HGF cells. These results suggested that crizotinib plus
a new generation EGFR-TKI can overcome resistance to a new
generation EGFR-TKI by inhibiting the phosphorylation of
Figure 3.  Crizotinib reduces Met phosphorylation and combined treatment with a new generation EGFR-TKI inhibits
downstream pathways even in the presence of HGF.  H1975 and H1975/HGF cells were incubated with crizotinib (300 nmol/L)
and/or afatinib (300 nmol/L) (A, B) or WZ4002 (300 nmol/L) (C, D), for 1 hour. After stimulation with HGF (10 ng/mL) for 10 minutes,
the cell lysates were harvested and the phosphorylation of indicated proteins was determined by western blot analysis. Each sample
was assayed in triplicate, with each experiment repeated at least 3 times independently.
doi: 10.1371/journal.pone.0084700.g003
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EGFR and Met proteins, followed by inhibiting downstream Akt
and ERK1/2 in vivo.
To further assess the mechanism of action of combined
therapy, we assayed proliferation (Figure 4C, 4D, 5C, 5D) and
apoptosis (Figure 4C, 4E, 5C, 5E) in H1975/Vec- and H1975/
HGF-induced tumors. Treatment of mice carrying H1975/HGF-
tumors with afatinib (Figure 4C, 4D, 4E) or WZ4002 (Figure 5C,
5D, 5E), but not with crizotinib alone, significantly reduced the
number of proliferating cells and increased the number of
apoptotic cells compared with control, untreated mice.
Similarly, treatment with crizotinib plus afatinib (Figure 4A) or
WZ4002 (Figure 5A) had a greater effect than any agent alone,
with the greatest effect observed with WZ4002 plus high dose
crizotinib. These results suggested that the combination use of
a new generation EGFR-TKI and crizotinib inhibited tumor
growth by decreasing cell proliferation and increasing cell
apoptosis.
Figure 4.  Crizotinib combined with irreversible EGFR-TKI overcomes multiple resistances to EGFR-TKI in vivo.  (A) SCID
mice-bearing H1975/Vec- or H1975/HGF- tumors were administered afatinib (25 mg/kg) and/or crizotinib (10mg/kg) once daily for 6
to 20 days. Tumor volume was measured using calipers on the indicated days. Mean ± SE tumor volumes are shown for groups of 5
mice. *, P < 0.05 versus control; ✝, P < 0.05 versus afatinib (25 mg/kg) by one-way ANOVA. (B) H1975/Vec- or H1975/HGF- tumors
were resected from the mice 3 hours after administration of afatinib (25mg/kg) and/or crizotinib (10 mg/kg), and the relative levels of
proteins in the tumor lysates were determined by western blot analysis. (C) Representative images of H1975/Vec- and H1975/HGF
tumors immunohistochemically stained with antibodies to human Ki-67, and stained with both DAPI (nuclear stain) and TUNEL
(FITC). Bar, 200 μm. (D) Quantification of proliferative cells, as determined by their Ki-67-positive proliferation index (percentage of
Ki-67-positive cells). Quantification of apoptotic cells, as determined by the TUNEL assay as described in Materials and Methods.
Columns, mean of five areas; bars, SD. *, P < 0.05 versus H1975/Vec-tumors; ✝, P < 0.05 versus control of H1975/HGF-tumors by
one-way ANOVA.
doi: 10.1371/journal.pone.0084700.g004
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Toxicity profiles of new generation EGFR-TKIs plus
crizotinib
To evaluate the toxicities of afatinib or WZ4002 when
combined with crizotinib, we analyzed mouse body weight
(Figure 6A, 6B) and intestinal mucosal damage (Figure 6C,
Figure S5, S6) during treatment in vivo. Histological analysis
showed that the combination of afatinib and high dose
crizotinib (25mg/kg/day) induced lethal toxicity, including
severe intestinal mucosal damage and loss of body weight
(Figure 6A, 6C), indicating that long-term treatment with the
combination of an irreversible EGFR-TKI and crizotinib may
cause severe, even fatal, toxicities. In contrast, the combination
of the mutant-selective EGFR-TKI WZ4002 and high or low
dose of crizotinib had little effect on intestinal mucosal histology
or mouse weight (Figure 6B, 6C). Treatment with low dose
crizotinib alone, afatinib alone, or WZ4002 alone had little
effect on the intestinal mucosa and mouse weight, suggesting
that combination therapy, not any agent alone, causes severe
toxicities.
Figure 5.  Crizotinib combined with mutant-selective EGFR-TKI overcomes multiple resistances to EGFR-TKI in vivo.  (A)
SCID mice-bearing H1975/Vec- or H1975/HGF- tumors were administered WZ4002 (25 mg/kg) and/or crizotinib (10, 25mg/kg) once
daily for 6 to 20 days. Tumor volume was measured using calipers on the indicated days. Mean ± SE tumor volumes are shown for
groups of 5 mice. *, P < 0.05 versus control; ✝, P < 0.05 versus WZ4002 by one-way ANOVA. (B) H1975/Vec- or H1975/HGF-
tumors were resected from the mice 3 hours after administration of WZ4002 (25mg/kg) and/or crizotinib (10, 25 mg/kg), and the
relative levels of proteins in the tumor lysates were determined by western blot analysis. (C) Representative images of H1975/Vec-
and H1975/HGF- tumors immunohistochemically stained with antibodies to human Ki-67, and stained with both DAPI (nuclear stain)
and TUNEL (FITC). Bar, 200 μm. (D) Quantification of proliferative cells, as determined by the Ki-67-positive proliferation index
(percentage of Ki-67-positive cells). Quantification of apoptotic cells, as determined by the TUNEL assay as described in Materials
and Methods. Columns, mean of five areas; bars, SD *, P < 0.05 versus of H1975/Vec-tumors; ✝, P < 0.05 versus H1975/HGF-
tumors by one-way ANOVA.
doi: 10.1371/journal.pone.0084700.g005
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Discussion
Many attempts have been made to overcome the resistance
of lung cancers refractory to reversible EGFR-TKIs and
harboring EGFR activating mutations. Although irreversible
EGFR-TKIs such as afatinib have been tested in clinical trials
for EGFR-TKI-refractory lung cancer, monotherapy with agents
of this class has shown minimum benefits with severe adverse
effects [32]. Of patients with EGFR mutant lung cancer,
26-40% had tumors with high HGF expression and EGFR-
T790M secondary mutation, 5-33% had tumors with Met gene
amplification and EGFR-T790M secondary mutation, and 4-7%
had tumors with high HGF expression and Met gene
amplification, suggesting that dual targeting of HGF/Met and
the EGFR-T790M mutation may overcome resistance to
EGFR-TKIs [23,25,33].
HGF was originally identified as a hepatocyte mitogen and
has since been shown to have pleiotropic biological activities
[29]. HGF and its receptor Met are expressed at various levels
in various types of cancer cells [24]. Many lung cancer cells
express Met, with these cells and others in their
microenvironment expressing their Met ligands [34], suggesting
that these receptors and ligands modulate the sensitivity of
cancer cells to molecular targeted drugs in their
microenvironment.
The lack of response of EGFR-TKI resistance tumors to
monotherapy may be caused by the heterogeneity of
resistance mechanisms. We therefore assessed methods to
overcome resistance to multiple drugs caused by EGFR and/or
Met signaling without causing severe adverse effects. Here, we
focused on crizotinib as a Met inhibitor. Although approved by
the U.S. Food and Drug Administration as an ALK inhibitor,
crizotinib was found to be a potent Met inhibitor, with an IC50
for wild type c-Met of 4 nM. Moreover, this agent was clinically
safe, suggesting that it may be a candidate for overcoming the
HGF-Met axis induced resistance to reversible EGFR-TKIs.
Figure 6.  Toxicity profiles of crizotinib plus afatinib or WZ4002 in vivo.  (A), (B), Relative body weight of mice during treatment
with afatinib or WZ4002 and/or crizotinib. Mean ± SD body weights are shown for groups of 5 mice. (C), Quantification of mucosal
damage by injury index of intestinal sections (black column: large intestine, white column: small intestine), as determined by H&E
staining. Each column represents the mean of two areas for groups of 5 mice; bars, SD.
doi: 10.1371/journal.pone.0084700.g006
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Dual blockade of HGF/Met and mutant EGFR was shown to
overcome the resistance to EGFR-TKIs caused by EGFR-
T790M mutation and Met gene amplification in a preclinical
model [33]. We have extended these findings, showing that
crizotinib plus afatinib or WZ4002 could overcome EGFR-TKI
caused by HGF overexpression in both autocrine and paracrine
systems, as well as resistances caused by the gatekeeper
EGFR-T790M mutation and Met gene amplification. Dual
blockade of HGF/Met and mutant EGFR may therefore
overcome concurrent resistance to EGFR-TKIs. The strongest
anti-tumor effects were exhibited by the combination of high
dose crizotinib and a new generation EGFR-TKI, which
reduced tumor proliferation and increased tumor apoptosis in
vivo, indicating that complete dual blockade of mutant EGFR
and Met may overcome resistance to EGFR-TKIs.
Importantly, we observed severe toxicity, such as intestinal
mucosal damage and weight loss, when high dose crizotinib
and afatinib were combined. These lethal toxicities were not
observed when WZ4002 was combined with crizotinib,
suggesting that afatinib, but not WZ4002, inhibited wild type
EGFR which express in the intestinal mucosa. Moreover, these
findings indicated that adverse effects should be carefully
evaluated in clinical trials with combinations of agents targeting
both EGFR and Met.
Several strategies have been proposed to overcome
resistance to reversible EGFR-TKIs, including treatment with
afatinib, an anti-EGFR antibody [35], Hsp90 inhibitors [36],
PI3K/mTOR inhibitor [37], and mutant-selective EGFR-TKIs
[22]. Of them, mutant-selective EGFR-TKIs have shown activity
not only against tumors harboring exon19 deletions and the
L858R mutation, but against tumors with the T790M resistance
mutation. In addition, these agents may be less toxic than
traditional EGFR-TKIs since they target EGFR carrying only
certain specific mutations. Further clinical development of this
class of inhibitors in EGFR-mutant lung cancer patients who
become refractory to reversible EGFR-TKIs is warranted.
In summary, we found that crizotinib combined with a new
generation EGFR-TKI may overcome multiple resistances of
lung tumors to reversible EGFR-TKIs. These agents may inhibit
tumor proliferation and promote tumor apoptosis via blockade
of both mutant EGFR and Met signaling. These findings
suggest that treatment with crizotinib plus a new generation
EGFR-TKI, especially one selective for mutant EGFR, may
result in more successful outcomes in lung cancers with
resistance to EGFR-TKIs through the mutant EGFR and/or
HGF/Met pathways.
Supporting Information
Figure S1.  HGF dose-dependently induced resistance to
afatinib in lung cancer cells harboring EGFR mutations.
PC-9, HCC827, PC-9/KGR1, and H1975 cells (2×103 cells per
well) were incubated with various concentrations of afatinib and
HGF (0, 10, 20, 50 ng/mL) for 72 hours. Cell growth was
determined by the MTT assay. The percentage of growth is
shown relative to untreated controls. Each sample was
assayed in triplicate, with each experiment repeated at least 3
times independently.
(TIF)
Figure S2.  HGF dose-dependently induced resistance to
WZ4002 in lung cancer cells harboring EGFR mutations.
PC-9, HCC827, PC-9/KGR1, and H1975 cells (2×103 cells per
well) were incubated with various concentrations of WZ4002
and HGF (0, 10, 20, 50 ng/mL) for 72 hours. Cell growth was
determined by the MTT assay. The percentage of growth is
shown relative to untreated controls. Each sample was
assayed in triplicate, with each experiment repeated at least 3
times independently.
(TIF)
Figure S3.  Specific downregulation of Met, but not ALK,
reversed afatinib (300nmol/L) or WZ4002 (300nmol/L)
resistance induced by HGF (10ng/mL) in H1975 cells. The
percentage of growth is shown relative to untreated controls.
Each sample was assayed in triplicate, with each experiment
repeated at least 3 times independently. *, P < 0.05 by one-way
ANOVA. Downregulation of Met or ALK by specific-siRNA was
assessed by immunoblotting.
(TIF)
Figure S4.  Crizotinib overcomes resistance to new
generation EGFR-TKIs caused by fibroblast-derived HGF.
Tumor cells (8 × 103 cells/800 μL) were cultured with or without
afatinib (100 nmol/L) (A) or WZ4002 (100nmol/L) (B) in the
lower chambers of Transwell Collagen-Coated chambers.
MRC-5 cells (1 × 104 cells/300 μL), which were or were not
pretreated for 2 hours with anti-human HGF antibody (5 μg/mL)
or crizotinib (100 nmol/L) were placed in the upper chambers,
and the cells were cocultured for 72 hours. The number of cells
in the lower chamber was determined by the MTT assay.
Percent growth was relative to untreated controls. All samples
were assayed at least in triplicate, with each experiment
performed three times independently. *, P < 0.05 by one-way
ANOVA.
(TIF)
Figure S5.  Representative mucosal damage to the small
intestine, as assessed by H&E staining.
(TIF)
Figure S6.  Representative mucosal damage to the large
intestine, as assessed by H&E staining.
(TIF)
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